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Background: This study evaluated efficacy and safety of intravenous subanesthetic doses 
of esketamine using an administration time of 10 minutes in patients with treatment-resistant 
depression and bipolar depression.
Methods: A retrospective chart review was conducted to identify patients who met the inclu-
sion criteria for treatment-resistant depression and bipolar depression according to Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria, and these 
patients received rapid infusion of esketamine between June 2012 and December 2015. The 
Montgomery–Åsberg Depression Rating Scale (MADRS) was administered to measure and 
score depressive symptom severity before infusion and at 24 hours, 72 hours, and 7 days after 
infusion. In addition, Clinical Global Impression scale was administered before and 7 days 
after esketamine infusion.
Results: Esketamine was administered to 30 patients. A total of 27 patients met the inclusion 
criteria and had MADRS evaluation data, which showed that 23 had unipolar and 4 had bipolar 
depression. Thirteen patients (48.1%) showed therapeutic response (MADRS reduction 50%) 
within 1 week (7 days) of intervention. Remission (MADRS 7) was observed in 10 patients 
(37.0%) in the same period. Therapeutic response and remission frequencies were seen in 
16 (59.3%) and 11 (40.7%) patients, respectively, within 24 hours following drug infusion. The 
most relevant side effect observed during the esketamine infusion was dissociative symptoms 
ranging from mild to severe, which was reported by 11.1% of patients as a very disturbing 
experience.
Limitations: This study was done retrospectively, had a small sample size, and there was no 
comparative group.
Conclusion: The present study demonstrates that rapid infusion of esketamine is possibly not the 
optimal choice to administer this drug for treatment-resistant depression due to tolerability reasons. 
Further controlled studies are required to investigate efficacy, safety, and tolerability profiles 
among the different types of ketamines and methods of using this drug in depressed patients.
Keywords: tolerability, S-(+)-ketamine, treatment-resistant depression, dissociative symptoms, 
efficacy, safety
Introduction
Major depressive disorder is a debilitating mental illness that affects millions of subjects 
worldwide, leading to severe clinical and socioeconomic consequences.1 About one-
third of patients with major depressive disorder do not achieve remission from currently 
available treatments and could be considered as having treatment-resistant depression 
(TRD), which is associated with chronicity, higher morbidity, functional disability, 
and economic loss.2–6 In addition, TRD patients are affected by more comorbidities 
than non-TRD patients.7
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Current limitations of available antidepressants include 
delays in therapeutic effects from several weeks to months and 
low remission rates.8,9 Revolutionizing the therapeutic options 
for TRD, ketamine (or RS-(±)-ketamine), an N-methyl- 
d-aspartate (NMDA) receptor antagonist, administered at 
subanesthetic doses can elicit robust, rapid, and sustained 
antidepressant effects in TRD.10 The majority of clinical 
trials that describe rapid antidepressant effects on TRD 
involve the RS-(±)-ketamine.11–15 A recently published trial 
performed by Singh et al17 reported the rapid antidepressant 
action of esketamine (S-(+)-ketamine) after a 40-minute 
intravenous (IV) infusion of either 0.20 mg/kg or 0.40 mg/
kg dose in patients with TRD. It was also demonstrated that 
a lower dose produced a better tolerability while maintain-
ing efficacy.
Recently, esketamine was referred to as a less dissociative 
drug than RS-(±)-ketamine.12 However, this comparison has 
been insufficiently studied since there are only a few publi-
cations regarding esketamine use on TRD and with limited 
diversity of posology.16,17 Consequently, there is little evi-
dence about the safety and tolerability profile of esketamine 
and its dissociative properties when used in TRD patients.
A crucial point related to ketamine use is safety, espe-
cially due to cardiovascular risks and abusive misuse.10 
Therefore, its administration requires clinical monitoring and 
other supporting services under medical supervision.10,13,14
Most protocols for ketamine administration adopt a time-
frame of 40 minutes for infusion. However, this parameter is 
not supported by evidence, considering that in anesthesiology 
it is common to use a higher dose of RS-(±)-ketamine 
(2 mg/kg) with faster speed of infusion lasting 5–10 minutes 
for IV administration, and this is particularly true regarding 
esketamine.18,19 We examined the efficacy, safety, and toler-
ability of off-label IV use of esketamine in TRD.
Materials and methods
This retrospective chart review was carried out at the 
inpatient unit at the Psychiatry Service at the University 
Hospital – Universidade Federal da Bahia, Salvador, Brazil. 
Patients were assessed between June 2012 and December 
2015, with the diagnosis of MDD and dipolar disorder being 
based upon Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition, Text Revision criteria (Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition, 
Text Revision [DSM-IV-TR], 2000); Montgomery–Åsberg 
Depression Rating Scale (MADRS)20 was administered to 
measure depressive symptom severity before infusion and 
at 24 hours, 72 hours, and 7 days after infusion of ketamine, 
and the Clinical Global Impression scale (CGI) was 
administered21 before and at 7 days after infusion.
TRD was defined as failure to respond to 2 or more trials 
using antidepressant therapy in adequate doses, with dura-
tions of at least 6 weeks each.
All the participants were undergoing naturalistic treat-
ment for depression and comorbidities, according to clinical 
demand. The clinical protocol excluded the use of esketamine 
in patients if they met any of the following criteria: psychotic 
disorder, previous dissociative disorders, comorbid dementia, 
substance use disorders, and/or uncontrolled hypertension.
The primary endpoints were remission of depressive 
symptoms and therapeutic response, defined as at least 50% 
improvement from baseline depression score. All adverse 
effects that emerged during infusion and at subsequent 
observation periods were also registered.
All subjects were treated with esketamine (Ketamin® 
Dextrocetamine hydrochloride Injectable Solution 50 mg/mL. 
Cristalia Produtos Químicos Farmarcêuticos Ltda, Itapira, 
Brazil) at a standard dose of 0.25 mg/kg administered IV 
for a duration of 10 minutes.
The study was approved by the local Institutional 
Review Board (Complex University Hospital Professor 
Edgard Santos – Federal University of Bahia – Number: 
43645915.1.10000.0049). The Research Ethics Committee – 
University Hospital Prof Edgard Santos (Local Institutional 
Review Board) waived the need for patient consent for this 
retrospective review since all data were anonymized and 
kept confidential.
Statistical analysis
A summary of statistical parameters (mean, standard devia-
tion, median, interquartile range, minimum, and maximum) 
are reported for the MADRS score at each point in time. 
Quantitative temporal differences among time points were 
tested, controlling for clinical comorbidities, through a linear 
mixed effects model. The model was fit with one fixed inter-
cept, Time and Presence of Clinical Comorbidity as fixed 
effect, and one random intercept for every patient, allowing 
for the analysis of data without data imputation or patient 
exclusion from the sample.22 Assumptions of normality of 
the residuals and homogeneity of variance were verified 
through QQ Plot and graphical analysis of predicted values 
and residuals. Mean differences were estimated from the 
model through Tukey contrasts.
Absolute and relative (percentage) frequencies of remis-
sion of depressive symptoms and therapeutic response are 
reported. All relative frequencies (percentage) are related to 
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the initial number of patients included. MADRS scores among 
these groups are also reported. All analyses were conducted in 
R Environment and Programming Language (version 3.3.1); 
mixed effects model was fit using lme4 (version 1.1.12) pack-
age with restricted maximum likelihood method (REML).
Results
general characteristics
Sociodemographic characteristics are displayed in Table 1.
Depressive symptoms and baseline 
characteristics
Initially, our sample consisted of 30 patients, but MADRS 
data was not available for 3 of them, hence 27 were 
finally included. Therefore a retrospective chart review is 
reported for 23 patients with TRD and 4 with bipolar depres-
sion, who all received a low-dose of esketamine administered 
very quickly: time duration 10 minutes.
The majority of participants had chronic depressive 
symptoms, and all of them had presented at least 2 failed 
trials using antidepressants.
The patients presented a high MADRS mean score 
(36.2±7.6) prior to intervention. The median of onset age 
of major depressive episode was 38 years, with half of the 
patients ranging from 26.0 to 50.0 years. All patients pre-
sented a lifetime history of major depressive episode with an 
average of 4.0 episodes (interquartile range: 2.8–6.0). Four 
patients (14.8%) were bipolar. The most common psychiatric 
comorbidities were obsessive compulsive disorder (11.1%) 
and social phobia (11.1%). All patients from this study 
were treated with antidepressants, 20 (74.1%) used atypical 
antipsychotics, and only 5 (18.5%) used lithium (the others 
had prior therapeutic failure with this drug and/or had con-
traindications to using it). Benzodiazepine usage was present 
in 13 patients (48.1%). Most subjects (17 individuals; 63.0% 
of the sample) did not have medical comorbidities. Among 
those who presented medical comorbidities, cardiovascular 
diseases were the most common (33.3%), followed by endo-
crine diseases (18.5%) and cancer (7.4%).
Therapeutic response
Average values of MADRS showed reductions during 
follow-up time. A summary of the statistics is displayed in 
Table 2 and Figure 1.
Thirteen patients (48.1%) displayed therapeutic response 
(MADRS score reduction 50%) within 1 week (7 days) 
after intervention. Remission (MADRS 7) was observed 
in 10 patients (37.0%) in the same time period. Therapeutic 
response and remission frequencies were observed in 
16 patients (59.3%) and 11 patients (40.7%), respectively, 
within 24 hours after drug infusion.
The mixed effects model converged to a unique solution 
(REML criterion =716.04; random effect SD =10.636; fixed 
intercept =34.473). Fixed-effect estimate for the presence 
of medical comorbidity was positive (estimate =3.397; 
standard error =4.929), although not significant (Type II 
Wald χ2=0.475; df=1; P=0.491). Time factor was signifi-
cant (Type II Wald χ2=66.846; df=3; P0.001), with large 
estimated mean differences between the time points Before 
Intervention and the remaining follow-up points (24 hours – 
BI: -18.73±2.31; 72 hours – BI: -17.51±2.34; 7 days – 
BI: -17.16±2.34; all P-values 0.001).
Table 1 general clinical and epidemiological characteristics of 
the patient sample undergoing treatment with rapid infusion of 
esket amine
Variables Mean (min–max)
age 51.0 (42.0–64.0)
Years of education 15.0 (15.0–16.0)
N (%)
civil status
single 7 (25.0)
Married 14 (50.0)
Divorced 3 (10.7)
Widow 2 (7.1)
Male sex 17 (60.7)
ethnicity (self-declared)
caucasian 13 (46.4)
afro-Brazilian 13 (46.4)
Nondeclared 2 (7.2)
Occupation
student 1 (3.6)
remunerated occupation 15 (53.6)
Nonremunerated occupation 12 (42.8)
Main diagnosis
Depression unipolar 22 (78.6)
Depression bipolar 6 (21.4)
Psychiatric comorbidities
OcD 4 (14.3)
social phobia 4 (14.3)
PTsD 2 (7.1)
gaD 2 (7.1)
Panic disorder 2 (7.1)
aDhD 2 (7.1)
agoraphobia 1 (3.6)
Benzodiazepine use 13 (46.4)
clinical comorbidities
cardiovascular disease 7 (25.0)
endocrine disease 5 (17.9)
cancer 1 (3.6)
Abbreviations: OcD, obsessive compulsive disorder; PTsD, posttraumatic stress 
disorder; GAD, generalized anxiety disorder; ADHD, attention-deficit hyper-
activity disorder.
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safety
Vital signs, electrocardiograms, and clinical laboratory 
assessments were within normal ranges. No deaths occurred 
in the cases reviewed. No clinically significant changes in 
laboratory tests, electrocardiograms, or physical examinations 
were observed in the week following esketamine infusion.
The most relevant side effect observed was mild to 
severe dissociative symptoms. Three patients (11.1%) had 
psychomimetic effects during esketamine infusion, which 
presented as severe dissociative symptoms, and two of these 
cases showed remission within 3 weeks after esketamine 
administration.
Discussion
Previous clinical trials described the rapid action of NMDA 
antagonist ketamine after a single infusion in patients with 
TRD11,15,23,24 as well as the variable duration of antidepres-
sant effects ranging from 1 to several weeks.15,25Although it 
represents a major advance in the treatment of TRD, many 
questions remain about the efficacy and tolerability of this 
drug in depressed patients.
To our knowledge, this is the first report regarding rapid 
infusion time (10 minutes) of esketamine in TRD patients. 
The present results suggest that, despite the robust efficacy 
obtained in these naturalistically treated patients, this rate 
of drug administration produced certain severe dissociative T
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Figure 1 Temporal evolution of therapeutic remission of the patient sample upon 
rapid infusion esketamine treatment.
Note: Points represent means, and error bars show 95% confidence intervals 
estimated from standard errors.
Abbreviation: MaDrs, Montgomery–Åsberg Depression rating scale.
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side effects. These results were not modified by the presence 
of medical and psychiatric comorbidities. The finding that 
esketamine use may be associated with highly distressing 
symptoms related to the dissociative experience challenges 
previous studies that characterize the esketamine as more 
tolerable than the RS-(±)-ketamine.26 In four patients, the 
severity of side effects seemed to contradict the improvement 
of depressive symptoms.
The presence of dissociative symptoms has been observed 
as a predictor for a better antidepressant effect of ketamine. 
However, this is a limited finding from only one study with 
many limitations such as secondary data analysis, com-
bined diagnostic groups, potential unblinding, and small 
sample sizes.27
The present findings should be interpreted with caution 
since several limitations inherent to using a retrospective 
design are present. They include the lack of a control group 
and lack of randomization. As this was not a controlled study 
and the subjects had taken several other medications that 
might modify antidepressant effects and pharmacokinetics of 
esketamine, we cannot assure whether the efficacy is related 
to esketamine use alone or is a result of combined effects 
of esketamine and concomitant medications. Additionally, 
no standardized clinical measures were used to evaluate 
psychomimetic adverse effects. Nevertheless, due to these 
limitations, a prospective, controlled study using different 
doses and time of infusion is strongly required to confirm 
the efficacy of the esketamine as a feasible option for elicit-
ing fast-acting antidepressant effects, with a reasonable side 
effect profile.
Conclusion
The present case series suggests that rapid infusion of 
esketamine has similar efficacy when compared with 
RS-(±)-ketamine data in the literature. On the other hand, 
esketamine seems to have poor tolerability when compared 
to the racemic formulation. However, the infusion rate used 
in the present study may explain, at least in part, this poor 
tolerability. Randomized, controlled studies comparing 
efficacy and tolerability of S-(+)- and RS-(±)-ketamine are 
needed to confirm the present findings.
Disclosure
The authors report no conflicts of interest in this work.
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